Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Boehringer Ingelheim
Express Scripts
Merck
Dow

Last Updated: February 3, 2023

CLINICAL TRIALS PROFILE FOR ERIBULIN MESYLATE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Eribulin Mesylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00047034 ↗ E7389 in Treating Patients With Advanced Solid Tumors Completed National Cancer Institute (NCI) Phase 1 2002-08-01 Phase I trial to study the effectiveness of E7389 in treating patients who have advanced solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
NCT00334893 ↗ Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed National Cancer Institute (NCI) Phase 2 2006-04-01 This phase II trial is studying how well eribulin mesylate works in treating patients with recurrent ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
NCT00337077 ↗ Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Completed National Cancer Institute (NCI) Phase 2 2006-11-01 This phase II trial is studying how well eribulin mesylate (E7389; Halichondrin B Analog) works in treating patients with metastatic prostate cancer that did not respond to hormone therapy. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
NCT00337103 ↗ E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes Completed Eisai Inc. Phase 3 2006-09-20 The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy. This is an open-label, randomized, two-parallel arm study. Patients will be randomized to receive either E7389 or capecitabine on a one-to-one ratio.
NCT00337129 ↗ S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed National Cancer Institute (NCI) Phase 2 2006-05-01 RATIONALE: Drugs used in chemotherapy, such as E7389, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well E7389 works in treating patients with metastatic or recurrent head and neck cancer.
NCT00365157 ↗ Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Active, not recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2006-10-23 This phase I/II trial studies the effect of eribulin mesylate and to see how well it works in treating patients with cancer of the urothelium that has spread to nearby tissue (locally advanced) or to other places in the body (metastatic)and kidney dysfunction. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemotherapy drugs may have different effects in patients who have changes in their kidney function.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Eribulin Mesylate

Condition Name

Condition Name for Eribulin Mesylate
Intervention Trials
Breast Cancer 20
Metastatic Breast Cancer 14
Solid Tumors 3
Stage IV Urethral Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Eribulin Mesylate
Intervention Trials
Breast Neoplasms 48
Neoplasms 8
Carcinoma 8
Triple Negative Breast Neoplasms 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Eribulin Mesylate

Trials by Country

Trials by Country for Eribulin Mesylate
Location Trials
United States 479
Japan 58
Canada 25
Spain 14
India 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Eribulin Mesylate
Location Trials
New York 26
California 25
Texas 23
Florida 22
Washington 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Eribulin Mesylate

Clinical Trial Phase

Clinical Trial Phase for Eribulin Mesylate
Clinical Trial Phase Trials
Phase 4 3
Phase 3 7
Phase 2 40
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Eribulin Mesylate
Clinical Trial Phase Trials
Completed 45
Recruiting 12
Active, not recruiting 8
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Eribulin Mesylate

Sponsor Name

Sponsor Name for Eribulin Mesylate
Sponsor Trials
Eisai Inc. 29
National Cancer Institute (NCI) 23
Eisai Co., Ltd. 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Eribulin Mesylate
Sponsor Trials
Industry 60
Other 52
NIH 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Johnson and Johnson
Dow
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.